Overview

Management

Advisors

Funding

Contact

Advisors

Tom Bishop

Business Advisor

Tom Bishop

Mr. Bishop has a dynamic 20 year career in the biotech industry including all aspects of business development, sales and operations. He is currently Chief Business Officer at Emerald Bio. He previously held positions as VP of Commercial Operations at Microlytic and as Site Leader and Director of Sales at Exiqon NA. At Exiqon NA, he led commercial operations and was responsible for growing revenue from start-up in 2006 to ~$16M in 2010. His early career also includes stints at Ambion and Invitrogen where he had a demonstrated track record of generating continued sales growth. Mr Bishop brings his skills to guide Circulomics' commercial launch, operation, and sales strategies.

Brad Calvin

Business Advisor

Brad Calvin

Mr. Calvin has 25 years of experience leading the marketing, sales, and product development of diagnostic tests and medical devices. He's held executive positions at Abbott, Beckman Coulter, Qiagen/Digene, and Agenix. At Beckman Coulter, Mr. Calvin was General Manager of the flow cytometry business unit. He is currently founder and president of AsedaSciences, which provides high-throughput phenotypic screening to the pharmaceutical industry. Mr. Calvin's expertise guides Circulomics' marketing and Go-To-Market strategies.

Dr. Tza-Huei Wang

Scientific Collaborator

Jeff Wang

Dr. Wang is a Professor of Biomedical and Mechanical Engineering at Johns Hopkins University. He leads an active research program at the crossroads of microfluidic, single molecule, and nanotechnologies with the aim of developing the next generation of translational clinical assays. Dr. Wang plays a prominent role in large translational cancer research projects including the $14M Cancer Center of Nanotechnology Excellence and Stand Up 2 Cancer. Dr. Wang serves as a valuable scientific advisor and collaborator in the development of Circulomics’ novel assay platforms.

Dr. Stephen Meltzer

Clinical Collaborator

Stephen Meltzer

Dr. Meltzer is a Professor of Medicine and Oncology at Johns Hopkins University, Division of Gastroenterology. He is the Director of GI Early Detection Biomarkers Laboratory and an expert on the molecular, genetic, and epigenetic basis of premalignant and malignant esophageal lesions. He is one of the first investigators to discover microRNA alterations in esophageal cancer (EC) and to identify circulating biomarkers in EC patients. He has published 152 original scientific papers in high-impact scientific journals. Dr. Meltzer acts as a clinical advisor and collaborator in the application of Circulomics’ assays toward management of GI cancers.